Fourteen-year experience with homovital homografts for aortic valve replacement.

Two hundred seventy-five unprocessed, viable homograft ("homovital") aortic valves were used for aortic valve replacement in patients aged 1.5 to 79 years (mean 45.8 +/- 19 years) with maximum follow-up of a 14-year period (mean 4.8 years). Ninety-two percent (252 patients) had New York Heart Association class III or IV functional status before operation and 25 underwent emergency operation. Valves were harvested under sterile conditions and kept in nutrient medium 199. Freehand (subcoronary) technique was used in 147 patients and freestanding root replacement was used in 128. Cumulative survival rates for the whole group were 92% +/- 2% at 5 years and 85% +/- 3% at 10 years, as compared with 96% +/- 2% and 94% +/- 4%, respectively, for the 98 patients who underwent isolated root replacement. Multivariate analysis determined that root replacement with associated procedures and operation for prosthetic endocarditis were risk factors for death, whereas previous xenograft valve, operation for endocarditis, and operation for aortic regurgitation were risk factors for reoperation. Actuarial rates for freedom from degenerative valve failure diagnosed at operation, by postmortem examination, or by routine echocardiography were 94% +/- 2% at 5 years and 89% +/- 3% at 10 years. Recipient age younger than 30 years and previous xenograft valve were risk factors for late degeneration. We conclude that homovital valves demonstrate good durability, particularly in patients older than 30 years, who had a 10-year freedom from degeneration rate of 97%.

[1]  G. Christie,et al.  Identification of a Failure Mode of the Antibiotic Sterilized Aortic Allograft After 10 Years: Implications for Their Long‐Term Survival , 1991, Journal of cardiac surgery.

[2]  L. Wolfinbarger,et al.  The effect of liquid nitrogen submersion on cryopreserved human heart valves. , 1990, Cryobiology.

[3]  E. Bove,et al.  Effect of cryopreservation on the presence of endothelial cells on human valve allografts. , 1993, The Journal of thoracic and cardiovascular surgery.

[4]  D. Ross,et al.  Elasticity of frozen aortic valve homografts. , 1977, Cardiovascular research.

[5]  E. Arbustini,et al.  Calcific degeneration as the main cause of porcine bioprosthetic valve failure. , 1984, The American journal of cardiology.

[6]  Magdi H. Yacoub,et al.  Applications and limitations of histocompatibility in clinical cardiac valve allograft surgery , 1988 .

[7]  T. Grehl,et al.  Long-term follow-up of viable frozen aortic homografts. A viable homograft valve bank. , 1987, The Journal of thoracic and cardiovascular surgery.

[8]  R. Wallace,et al.  Long-term results of aortic valve replacement with nonviable homografts. , 1991, Circulation.

[9]  W. Dixon,et al.  BMDP statistical software , 1983 .

[10]  R. Scully,et al.  AGING CHANGES IN THE AORTIC AND MITRAL VALVES. HISTOLOGIC AND HISTOCHEMICAL STUDIES, WITH OBSERVATIONS ON THE PATHOGENESIS OF CALCIFIC AORTIC STENOSIS AND CALCIFICATION OF THE MITRAL ANNULUS. , 1965, The American journal of pathology.

[11]  M. Yacoub,et al.  Homograft replacement of the aortic valve. A critical review. , 1969, Progress in cardiovascular diseases.

[12]  J. Bonnar,et al.  Letter: Subcutaneous heparin. , 1974, Lancet.

[13]  R. Subramanyan,et al.  Long-term follow-up of patients with the antibiotic-sterilized aortic homograft valve inserted freehand in the aortic position. , 1987, Circulation.

[14]  Barratt-Boyes Bg.  Homograft replacement for aortic valve disease. , 1967 .

[15]  D N Ross,et al.  Replacement of aortic and mitral valves with a pulmonary autograft. , 1967, Lancet.

[16]  M. Yacoub.  Allograft aortic root replacement , 1988 .

[17]  D N Ross,et al.  Homograft replacement of the aortic valve. , 1962, Lancet.

[18]  A. C. Yankah,et al.  Cardiac Valve Allografts 1962–1987 , 1988, Steinkopff.

[19]  P. Myerowitz,et al.  The fate of aortic valve homografts 12 to 17 years after implantation. , 1988, Chest.

[20]  M. Petrou,et al.  The use of unstented homograft valves for aortic valve reoperations. Review of a twenty-three-year experience. , 1994, The Journal of thoracic and cardiovascular surgery.

[21]  D N Ross,et al.  Protein synthesis in fresh aortic and pulmonary value allografts as an additional test for viability. , 1973, Cardiovascular research.

[22]  A. C. Yankah,et al.  Antigenicity and fate of cellular components of heart valve allografts , 1988 .

[23]  M. Yacoub,et al.  Patient status 10 or more years after 'fresh' homograft replacement of the aortic valve. , 1984, Circulation.

[24]  P. Spratt,et al.  [Surgical treatment with aortic valve homograft harvested from heart transplant recipients or donors]. , 1993, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai.

[25]  F. Lupinetti,et al.  Immunogenicity, Antigenicity, and Endothelial Viability of Aortic Valves Preserved at 4°C in a Nutrient Medium , 1991 .

[26]  O. Lund.  Valve replacement for aortic stenosis: the curative potential of early operation. , 1993, Scandinavian journal of thoracic and cardiovascular surgery. Supplementum.

[27]  M. Yacoub,et al.  End-stage dilated cardiomyopathy. Persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response. , 1989, Circulation.

[28]  D C Naftel,et al.  Long-term function of cryopreserved aortic homografts. A ten-year study. , 1993, The Journal of thoracic and cardiovascular surgery.

[29]  D. Cox.  Regression Models and Life-Tables , 1972 .

[30]  M. O'Brien,et al.  A comparison of aortic valve replacement with viable cryopreserved and fresh allograft valves, with a note on chromosomal studies. , 1987, The Journal of thoracic and cardiovascular surgery.

[31]  R. Elkins.  Pulmonary autograft--the optimal substitute for the aortic valve? , 1994, The New England journal of medicine.